Sun Pharmaceutical Industries of India will acquire New Jersey-based Organon & Co in an all-cash deal valued at $11.75 billion, including debt. Sun Pharma will pay $14 per share to buy all outstanding Organon shares, a company spun off from Merck in 2021 specializing in women's health and biosimilars. This acquisition will raise Sun Pharma's revenue to $12.4 billion, placing it among the top 25 global pharmaceutical companies and significantly expanding its footprint in the US market. The deal also supports Sun Pharma's strategy to grow its innovative medicines business, increasing the contribution of this segment to 27% of total sales by fiscal 2025.
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
